Aprecia
Develops and manufactures 3D-printed pharmaceutical products using proprietary ZipDose® Technology for rapid-dissolving high-dose oral medications, with Spritam® as the first FDA-approved 3D-printed drug.
- CEO / Founder
- Owen Murray
- Team Size
- 51-200
- Stage
- Active
- Total Funding
- $176M
- Latest Round
- Debt
- Key Investors
- Deerfield Management; Ben Franklin Technology Partners; Blue Chip Venture; JW Asset Management; Hercules Capital
Technology & Products
Key Products
Spritam® (first FDA-approved 3D-printed drug); CustomRelease (precision drug delivery systems)
Technological Advantage
Proprietary ZipDose® Technology allows for precise layer-by-layer deposition of active ingredients and excipients, enabling high-dose formulations with rapid disintegration; protected by 126 granted patents and 52 pending.
Differentiation
Value Proposition
Enables production of high-dose (over 1000mg) medications that disintegrate rapidly in the mouth without water, improving patient compliance and addressing unmet treatment needs for conditions like epilepsy.
How They Differentiate
Holds first-mover advantage with FDA-approved commercial product (Spritam®) and extensive patent portfolio (126 granted), whereas competitors are in earlier stages or focus on different 3D printing processes like melt extrusion deposition.
Market & Competition
Target Customers
Branded, generic, OTC pharmaceutical, and nutraceutical partners
Industry Verticals
Pharmaceuticals; Healthcare; Medical
Competitors
BioZone Labs, LATITUDE Pharmaceuticals, Synthego
Growth & Milestones
Growth Metrics
Revenue estimated at $30.3 million with 63 employees; holds 126 granted patents and 52 pending.
Major Milestones
FDA approval of Spritam® in 2015 (first 3D-printed drug); Completion of $35 million financing led by Deerfield Management; Partnership with Battelle to scale 3D printed pharmaceutical manufacturing; Over 20 years of innovation in 3D printing pharma
Notable Customers
Prasco Laboratories